Chase Sun(SZ:300026) Zhong Guo Jing Ji Wang·2025-11-07 02:49Core Viewpoint - Hongri Pharmaceutical (300026.SZ) announced a share reduction plan involving major shareholders and senior management, which will not affect the company's control or governance structure [1][2]. Shareholder Reduction Plans - Major shareholder Yao Xiaoqing plans to reduce holdings by up to 46,936,332 shares, representing 1.5624% of the total share capital, within three months after a 15-day notice period [1]. - Senior management members Chen Ruiqiang and Zhang Kun plan to reduce their holdings by up to 169,000 shares (0.0056%) and 232,000 shares (0.0077%), respectively [1]. - The total reduction across all parties amounts to 47,337,332 shares, or 1.5757% of the total share capital [1]. Financial Implications - Based on the last closing price of 3.79 yuan per share, the total cash to be raised from the share reductions is approximately 179.41 million yuan, with Yao Xiaoqing expected to realize about 177.89 million yuan from his share sale [1]. Current Shareholding Structure - As of the announcement date, Yao Xiaoqing holds 300,415,428 shares (10.00%), Chen Ruiqiang holds 677,900 shares (0.0226%), and Zhang Kun holds 931,750 shares (0.0310%) [2]. - Yao Xiaoqing is the second-largest shareholder and has been reducing his stake since July 2013, having sold a total of 117 million shares for approximately 851 million yuan [2][3].